Working... Menu

Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02531126
Recruitment Status : Recruiting
First Posted : August 24, 2015
Last Update Posted : March 15, 2019
Information provided by (Responsible Party):

Brief Summary:
The purpose of the trial is to determine the long-term safety and efficacy of RPC1063 in patients diagnosed with moderate to severe ulcerative colitis.

Condition or disease Intervention/treatment Phase
Ulcerative Colitis Drug: RPC1063 Phase 3

Detailed Description:
The trial is an open label extension study. Eligible patients from the RPC01-3101 and RPC01-202 trials will have the option to enroll in this trial to receive study medication for up to 5 years or until marketed approval

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 890 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
Actual Study Start Date : December 2, 2015
Estimated Primary Completion Date : March 31, 2022
Estimated Study Completion Date : March 31, 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: RPC0163 (Ozanimod) Drug: RPC1063
Other Name: Ozanimod

Primary Outcome Measures :
  1. Safety as assessed by the evaluation of adverse events [ Time Frame: Up to 5 years ]
  2. Efficacy as assessed by Mayo component sub-scores [ Time Frame: Up to 5 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Previously participated in a trial of RPC1063 for UC and meet the criteria for participation in the open label extension as outlined in the prior trial
  2. Female patients of childbearing potential:

    Must agree to practice a highly effective method of contraception throughout the trial until completion of the safety follow-up visit. Highly effective methods of contraception are those that alone or in combination result in a failure rate of a Pearl index of less than 1% per year when used consistently and correctly. Acceptable methods of birth control in the trial are the following:

    • combined hormonal (oestrogen and progestogen containing) contraception, which may be oral, intravaginal, or transdermal
    • progestogen-only hormonal contraception associated with inhibition of ovula-tion, which may be oral, injectable, or implantable
    • placement of an intrauterine device (IUD)
    • placement of an intrauterine hormone-releasing system (IUS)
    • bilateral tubal occlusion
    • vasectomised partner
    • sexual abstinence

    Male patients:

    Must agree to use a latex condom during sexual contact with women of childbearing po-tential while participating in the trial until completion of the safety follow-up visit.

    All patients:

    Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhoea method are not ac-ceptable methods of contraception. Female condom and male condom should not be used together.

  3. Must provide written informed consent and have the ability to be compliant with the schedule of protocol assessments, which must be obtained prior to any trial-related procedures.

Exclusion Criteria:

  1. Have received any of the following therapies since the first dose of investigational drug in the prior RPC1063 trial:

    • Treatment with a biologic agent
    • Treatment with an investigational agent other than RPC1063
    • Treatment with D-penicillamine, leflunomide, thalidomide, natalizumab or fingolimod
    • Treatment with lymphocyte-depleting therapies (e.g., Campath, anti-CD4, cladribine, rituximab, ocrelizumab, cyclophosphamide, mitoxantrone, total body irradiation, bone marrow transplantation, alemtuzumab, daclizumab)
    • Treatment with a live vaccine within 4 weeks prior to Visit 1 of this trial
  2. Are currently receiving or require initiation of any of the following therapies:

    • Treatment with corticosteroids at a dose that exceeds the prednisone equivalent of >40 mg
    • Treatment with immunosuppressive agents (eg, azathioprine, 6-MP, or methotrexate)
    • Chronic non-steroidal anti-inflammatory drug (NSAID) use (Note: occasional use of NSAIDs and acetaminophen [eg, headache, arthritis, myalgias, or menstru-al cramps] and aspirin up to 325 mg/day is permitted)
    • Treatment with Class Ia or Class III anti-arrhythmic drugs or treatment with two or more agents in combination known to prolong PR interval
  3. Pregnancy, lactation, or a positive serum beta human chorionic gonadotropin (hCG)
  4. Clinically relevant hepatic, neurological, pulmonary, ophthalmological, endocrine, psychiatric or other major systemic disease making implementation of the protocol or interpretation of the trial difficult or that would put the patient at risk by participating in the trial or that would have required a patient to discontinue treatment in previous RPC1063 trial
  5. Clinically relevant cardiovascular conditions, including history or presence of recent myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, Class III/IV heart failure, sick sinus syndrome, or severe untreated sleep apnea
  6. Liver function impairment or persisting elevations of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 5 times the upper limit of normal (ULN), or direct bilirubin > 3 times the ULN
  7. FEV1 or FVC < 50% of predicted values

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02531126

Layout table for location contacts
Contact: Celgene True North Study True North Study 1-844-266-9299

  Show 275 Study Locations
Sponsors and Collaborators
Layout table for investigator information
Study Director: AnnKatrin Petersen, M.D., MSc. Celgene Corporation

Layout table for additonal information
Responsible Party: Celgene Identifier: NCT02531126     History of Changes
Other Study ID Numbers: RPC01-3102
2015-001600-64 ( EudraCT Number )
First Posted: August 24, 2015    Key Record Dates
Last Update Posted: March 15, 2019
Last Verified: March 2019

Additional relevant MeSH terms:
Layout table for MeSH terms
Colitis, Ulcerative
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Pathologic Processes
Inflammatory Bowel Diseases